Jordan firm develops novel coronary stent
Amman, September 12, 2012
Jordan-based Abu Sheikha Drugstore, a leading distributor of pharmaceutical and medical supplies, said it has developed the 'world's first bioabsorbable coronary stent' and is awaiting its registeration.
Abu Sheikha said the company has completed all procedures for registering the bioabsorbable vascular stent under the trade mark, Absorb at Jordan Food and Drug Administration (JFDA).
Absorb is made of Polylactide, a proven biocompatible material that is commonly used in medical implants such as absorbable sutures, and has been developed to replace the old bare and drug eluting metal stents used in the treatment of coronary artery diseases.
Commenting on the move, Taiseer Abu Sheikha, the general manager said: “We at Abu Sheikha Drugstore pay special keenness to supplying the medical sector in the Kingdom with the latest advances in the world of medicine to make it a destination of choice for patients seeking advanced healthcare services.”
“To ensure the best possible outcome from vascular device implantations, an elite team of Jordanian cardiology physicians will receive training in a number of the European medical centers on the successful deployment of the coronary device,” he stated.
The company will make the new scaffold developed by Abbott Vascular, the global leader in cardiac and vascular care, available to Jordan’s hospitals and medical centers within the few coming months, he added.-TradeArabia News Service
More Health & Environment Stories
- Bapco installs $120m water treatment plant
- $68bn health bill warning for GCC
- VLCC launches anti-obesity initiative in Bahrain
- 1,000 health experts at Doha innovation summit
- Major progress in fight against malaria
- MAF Dalkia, Dubai Aviation ink consultancy deal
- Summit highlights HR challenges in Arab health sector
- Saudi launches ambitious gene mapping project
- ADSW to focus on energy-water nexus
- Bahrain moves to combat marine pollution